Viatris マネジメント
マネジメント 基準チェック /34
Viatrisの CEO はScott Smithで、 Apr2023年に任命され、 の在任期間は 3.08年です。 の年間総報酬は$ 15.27Mで、 9.5%給与と90.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.11%を直接所有しており、その価値は$ 19.99M 。経営陣と取締役会の平均在任期間はそれぞれ2.1年と4.5年です。
主要情報
Scott Smith
最高経営責任者
US$15.3m
報酬総額
| CEO給与比率 | 9.48% |
| CEO在任期間 | 3.1yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 2.1yrs |
| 取締役会の平均在任期間 | 4.5yrs |
経営陣の近況
Recent updates
VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential
Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential
Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.
VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential
Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan?
Mar 20
VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations
Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk
Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential
Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential
Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns
Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance
Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance
Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead
Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead
The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth
Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.Aging Populations And Asia Markets Will Unlock Future Value
Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.Aging Populations And Asia Markets Will Unlock Future Value
The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
New Product Launches And Expense Savings Will Strengthen Future Operations
New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.Viatris: One Swallow Doesn't Make A Summer
Feb 27Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Jan 24Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
Jan 06Bargain Priced Viatris Reports Strong Q3 Earnings Results
Nov 08Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy
Oct 22CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Dec 31 2025 | US$15m | US$1m | -US$4b |
| Sep 30 2025 | n/a | n/a | -US$4b |
| Jun 30 2025 | n/a | n/a | -US$3b |
| Mar 31 2025 | n/a | n/a | -US$4b |
| Dec 31 2024 | US$15m | US$1m | -US$634m |
| Sep 30 2024 | n/a | n/a | -US$883m |
| Jun 30 2024 | n/a | n/a | -US$646m |
| Mar 31 2024 | n/a | n/a | -US$56m |
| Dec 31 2023 | US$16m | US$1m | US$55m |
報酬と市場: Scottの 総報酬 ($USD 15.27M ) は、 US市場 ($USD 14.60M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Scottの報酬は増加しましたが、会社は利益を上げていません。
CEO
Scott Smith (63 yo)
3.1yrs
在職期間
US$15,273,331
報酬
Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 3.1yrs | US$15.27m | 0.11% $ 20.0m | |
| Chief Financial Officer | 2.2yrs | US$5.59m | 0.0061% $ 1.1m | |
| Chief Administrative & Transformation Officer | less than a year | US$4.30m | 0.019% $ 3.3m | |
| Chief Commercial Officer | 2.1yrs | US$5.93m | 0.0092% $ 1.6m | |
| Chief Accounting Officer & Corporate Controller | 11yrs | US$5.52m | 0.031% $ 5.5m | |
| Chief Information Officer | 2.2yrs | データなし | データなし | |
| Head of Investor Relations & Capital Markets | no data | データなし | データなし | |
| Chief Legal Officer | less than a year | データなし | 0% $ 0 | |
| Chief People & Corporate Affairs Officer | less than a year | データなし | データなし | |
| Chief R&D Officer | 2.4yrs | データなし | データなし | |
| Chief Supply Officer | 2.1yrs | データなし | データなし | |
| Chief Strategy Officer | 1.1yrs | データなし | データなし |
2.1yrs
平均在職期間
51yo
平均年齢
経験豊富な経営陣: VTRSの経営陣は 経験豊富 であると考えられます ( 2.1年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 3.4yrs | US$15.27m | 0.11% $ 20.0m | |
| Independent Non-Executive Director | 6.3yrs | US$475.01k | 0.0088% $ 1.5m | |
| Independent Director | 5.5yrs | US$395.01k | 0.0096% $ 1.7m | |
| Independent Director | 3.4yrs | US$395.01k | 0.0054% $ 942.2k | |
| Independent Director | 5.5yrs | US$445.01k | 0.014% $ 2.4m | |
| Independent Director | 1yr | US$374.93k | 0.0022% $ 392.3k | |
| Independent Non-Executive Chairman | 13.3yrs | US$720.01k | 0.019% $ 3.3m | |
| Independent Vice Chairman & Lead Independent Director | 16.7yrs | US$525.01k | 0.014% $ 2.5m | |
| Independent Director | 1.9yrs | US$375.01k | 0.0040% $ 700.5k | |
| Independent Director | 1yr | US$324.93k | 0.0022% $ 392.3k | |
| Independent Director | 6.3yrs | US$445.01k | 0.010% $ 1.7m | |
| Independent Director | 3yrs | US$400.01k | 0.0054% $ 954.5k |
4.5yrs
平均在職期間
63.5yo
平均年齢
経験豊富なボード: VTRSの 取締役会 は 経験豊富 であると考えられます ( 4.5年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/03 20:21 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Viatris Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31
| アナリスト | 機関 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Aaron Gal | Bernstein |